HOME >> MEDICINE >> NEWS
Positive results for ACRUX's lead product in US Phase 3 trial

Acrux (ASX: ACR), the pharmaceutical company with unique technology for delivering drugs through the skin, today announced positive results in a US Phase 3 clinical trial of Evamist, its daily skin spray for prevention of symptoms associated with menopause. The trial was conducted by its US commercial partner VIVUS Inc. (NASDAQ: VVUS), which will now proceed to file a marketing application with the US Food and Drug Administration (FDA) in the second half of 2006.

Evamist is the most advanced commercial application of Acrux's patented delivery technology; if the FDA approves VIVUS' marketing application, Acrux's first product could be available to women in the USA in the second half of 2007. Several other products that use the same delivery technology are following close behind. The positive result of this Phase 3 trial is therefore a pivotal milestone for each of these products.

The Phase 3 trial assessed the safety and efficacy of Evamist for the treatment of hot flushes in menopausal women. The trial was a 12-week study of 457 menopausal women, conducted under a Special Protocol Assessment (SPA) from the FDA. Results showed that the most effective Evamist dose decreased the number of hot flushes by 78%. The reduction in frequency and severity of moderate to severe hot flushes was statistically significant compared with placebo for all three doses of Evamist evaluated.

Importantly, application site irritation was less than 1% and was mild in nature. The results from the trial will be discussed by VIVUS at an Analyst Day in New York on 18 May 2006.

"We believe these positive trial results along with this novel patient-preferred transdermal delivery system will establish Evamist as a superior estrogen therapy for the treatment of menopausal symptoms," stated Leland Wilson, president and chief executive officer for VIVUS. "We have worked diligently toward the development of this unique and easy-to-use product, and we are thrilled with
'"/>

Contact: Igor Gonda
61-38-379-0100
Research Australia
9-May-2006


Page: 1 2

Related medicine news :

1. Positive results more likely from industry-funded breast cancer trials
2. M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD
3. Positive parenting helps encourage healthy sun habits in children
4. Positive outcome of Medicare drug benefit
5. Positive study results for methylphenidate transdermal system
6. Positive study results for methylphenidate transdermal system
7. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
8. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma
9. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
10. Targeted, oral agent Enzastaurin shows favorable results
11. Childhood obesity intervention shows promising results

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Positive results for ACRUX lead product Phase trial

(Date:11/18/2014)... OpenWorks, one of America’s leading commercial cleaning ... Guild Invitational. The John C. Lincoln Health Foundation holds ... Desert Mission community programs. Open Works was a Tee ... held at Camelback Golf Club in Scottsdale. More than ... Desert Mission — including a food bank, children's dental ...
(Date:11/18/2014)... As children head back to school and ... fall as the perfect time to refresh their looks ... County facial plastic surgeon, has observed a trend this ... Gallery of Cosmetic Surgery he has noticed an increase ... surgery procedures. , “Non-invasive cosmetic treatments give my ...
(Date:11/18/2014)... Thompson HealthDay Reporter , MONDAY, ... the verge of burning out are more likely to develop ... so-called vital exhaustion -- a toxic combination of fatigue, irritability ... developing heart disease, researchers report. "In our increasingly busy ... think, when that stress is left unchecked for a period ...
(Date:11/17/2014)... A Diet Doc in-house clinical ... country are turning back the clock on aging, looking ... because the company has recently added their prescription anti-aging ... of prescription and non-prescription diet products and healthy living ... best anti-aging human growth hormone therapy to ...
(Date:11/17/2014)... (PRWEB) November 17, 2014 HIPAA Secure ... Noble Partners by members of the ASCII Group, a ... Awards were handed out at this year’s ASCII ... and a commitment to helping their peers grow successful ... received their awards at the Summit on October 23, ...
Breaking Medicine News(10 mins):Health News:OpenWorks Sponsors 2014 Lincoln Guild Invitational Golf Tournament Hosted by Scottsdale's Camelback Golf Club 2Health News:Orange County Facial Plastic Surgeon, Dr. Kevin Sadati Observes a New Trend of Non-invasive Cosmetic Surgery Procedures Becoming Increasingly Popular This Fall 2Health News:Orange County Facial Plastic Surgeon, Dr. Kevin Sadati Observes a New Trend of Non-invasive Cosmetic Surgery Procedures Becoming Increasingly Popular This Fall 3Health News:Feeling 'Worn Out'? Your Heart May Pay the Price 2Health News:Feeling 'Worn Out'? Your Heart May Pay the Price 3Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 2Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 3Health News:The ASCII Group Names HIPAA Secure Now! Esteemed Noble Partner at ASCII Success Summit 2014 2Health News:The ASCII Group Names HIPAA Secure Now! Esteemed Noble Partner at ASCII Success Summit 2014 3
(Date:11/18/2014)... ResMed (NYSE: RMD ), a leading innovator in ... personal sleep monitoring device. ResMed today announced S+ availability through ... and from the Apple Online Store ( www.apple.com ). ... HealthKit in iOS8 to give consumers an easy-to-read, daily snapshot ... be shared with health care providers. "By ...
(Date:11/18/2014)... Nov. 18, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... Incorporated today announced the receipt of approval from the ... to market the IDEAL IMPLANT ® ... or replacement of existing augmentation implants. The FDA approval ... review of various studies and data including a U.S. ...
(Date:11/17/2014)... Ill. , Nov. 17, 2014  AbbVie (NYSE: ... Healthcare Conference in London on Thursday, ... and chief financial officer, will make a formal presentation on ... A live audio webcast of the presentation ... www.abbvieinvestor.com .  An archived edition of the session will ...
Breaking Medicine Technology:ResMed's New S+ Consumer Sleep Monitor Now Integrates With Apple HealthKit 2Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 2Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 3
Cached News: